NASDAQ

Updated Oct 30, 3:11 PM ET

OABI

OmniAb, Inc.

−$0.29 (5.64%) Today

Oct 30, 3:11 PM ET

About OABI

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Cylvex Score

Balanced

Neutral risk-reward, average coverage

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight
AnalystWall Street consensus & target distance
GrowthEarnings growth trajectory
ProfitabilityROE, margins, cash generation
ValuationPE, PEG, price-to-book ratios
TechnicalsPrice momentum & 52-week position
RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.